CinCor Pharma
CinCor Pharma Inc. is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. The company’s focus is on cardiovascular, metabolic and kidney diseases. CinCor Pharma was founded by Jon Isaacsohn, M.D., and Catherine Pearce, DHSc, MBA, in 2018.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Exit
Website
cincor.com
Related News
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
Acquisition of CinCor Pharma complete
CinCor Pharma to be acquired by AstraZeneca
CinCor Pharma announces topline data for Phase 2 HALO Trial evaluating selective aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension
CinCor Pharma announces publication in the New England Journal of Medicine of Phase 2 BrigHtn data on selective aldosterone synthase inhibitor baxdrostat in treatment-resistant hypertension
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.